Evidence map›Paper›PMID 36038018›Full record

ReviewPharmacology & therapeutics2022

Interplay between fat cells and immune cells in bone: Impact on malignant progression and therapeutic response.

Alexis Wilson, Laimar C Garmo, Izabela Podgorski

Abstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alexis WilsonDepartment of Pharmacology, Wayne State University School of Medicine, Detroit, MI, United States of America; Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI, United States of America.
Laimar C GarmoDepartment of Pharmacology, Wayne State University School of Medicine, Detroit, MI, United States of America.
Izabela PodgorskiDepartment of Pharmacology, Wayne State University School of Medicine, Detroit, MI, United States of America; Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI, United States of America. Electronic address: ipodgors@med.wayne.edu.
Wayne State University · US

Funding

Adipocyte regulation of tumor survival in metastatic prostate cancer: new targets for therapyR01CA251394 · NCI · WAYNE STATE UNIVERSITY · PI PODGORSKI, IZABELA · 2020 to 2024
$2.0M
ATF4-SCD axis in bone metastatic prostate cancerF31CA284576 · NCI · WAYNE STATE UNIVERSITY · PI WILSON, ALEXIS RYLEE · 2023 to 2024
$92k
NCI NIH HHS F31 CA284576NCI NIH HHS R01 CA251394
6 · The paper itself

Abstract

Bone is a frequent site of metastasis from several organs and a host for cancer cells that have originated from the bone marrow itself. Skeletal malignancies are extremely difficult to treat. This is largely due to the complex, heterogenous nature of the bone marrow microenvironment and the dynamic interplay between the tumor cells and multiple cell types within the marrow niche. One cell type whose dominant role in supporting tumor progression and therapy evasion is being increasingly recognized are bone marrow adipocytes (BMAs). BMAs are metabolically active endocrine cells that supply lipids, hormones and adipocytokines to the neighboring cells. Their numbers in bone marrow increase with age, obesity and in response to certain treatments and metabolic conditions. BMAs have been shown to directly promote tumor growth through a transfer of lipids, upregulation of lipid transporters, modulation of tumor metabolism and activation of adaptive stress mechanisms in the cancer cells to promote survival. Less is known, however, regarding how adipocyte interactions with other cell types in the bone tumor microenvironment support malignant progression. This review summarizes recent findings on the crosstalk between BMAs and immune cells in bone. We focus specifically on how adipocyte-mediated changes in the immune milieu impact the tumor cell survival and therapy response. We also discuss how adipocyte-immune cell interactions alter bone homeostasis to support malignant progression in a context of current therapeutic strategies for skeletal malignancies.

Indexed as

AdipocytesBone NeoplasmsAdipokinesHormonesHumansLipidsTumor MicroenvironmentAdipokinesHormonesLipidsBone marrow adiposityBone tumor microenvironmentER stressImmune cellsImmunometabolismLipid metabolism

Identifiers

PMID36038018
PMCPMC13638257
OpenAlexW4293577526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.